# GSK reports 5% Q3 sales growth and reaffirms 2026 guidance

- Link: https://www.directorstalkinterviews.com/gsk-reports-5-q3-sales-growth-and-reaffirms-2026-guidance/4121268196
- Published: 2026-10-28T07:07:00+00:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)(
[LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
has announced its Q3 results.**

_Strong Q3 performance and continued momentum_

| **Strong Specialty Medicines performance drives sales and core operating profit growth** | 
| • | Total Q3 sales £8.9 billion +4% AER; +5% CER | 
| • | Specialty Medicines sales £3.9 billion (+15%); HIV sales £2.1 billion (+10%), Respiratory, Immunology & Inflammation £1.1 billion (+21%); Oncology £0.6 billion (+23%) | 
| • | Vaccines sales £2.6 billion (-2%); _Shingrix_ £0.8 billion (-5%); Meningitis vaccines £0.6 billion (+12%); and _Arexvy_ £0.2 billion (-24%) | 
| • | General Medicines sales £2.4 billion (stable); _Trelegy_ £0.8 billion (+8%) | 
| • | Total operating profit -16% and Total EPS -21% driven by Major restructuring charges of £328 million related to the Accelerate Growth programme and lower other net operating income, partly offset by Core operating profit growth | 
| • | Core operating profit +5% and Core EPS +1% reflecting higher sales, favourable product and regional mix and higher royalty income, partly offset by increased investment in R&D and new asset launches and higher finance costs | 
| • | Cash generated from operations of £3.1 billion with free cash flow of £2.1 billion | 
| (Financial Performance – Q3 2026 results unless otherwise stated, growth % and commentary at CER as defined on page 43. The quarter and year to date adverse currency impact on AER versus CER primarily reflected the strengthening of Sterling against the USD. See page 8 for further details.) |

|   | **Q3 2026** | **Year to date** | 
|   | £m | % AER | % CER | £m | % AER | % CER | 
| Turnover | 8,887 | 4 | 5 | 24,925 | 4 | 5 | 
| Total operating profit | 2,127 | (18) | (16) | 4,901 | (28) | (25) | 
| Total operating margin % | 23.9% | (6.4ppts) | (6.1ppts) | 19.7% | (8.7ppts) | (8.2ppts) | 
| Total EPS | 38.5p | (23) | (21) | 92.5p | (26) | (23) | 
| Core operating profit | 3,076 | 3 | 5 | 8,526 | 5 | 7 | 
| Core operating margin % | 34.6% | (0.3ppts) | (0.1ppts) | 34.2% | 0.3ppts | 0.7ppts | 
| Core EPS | 54.6p | (1) | 1 | 151.6p | 4 | 6 | 
| Cash generated from operations | 3,122 | 24 |   | 7,378 | 18 |   |

| **Continued pipeline progress:** | 
| • | _Hibsago_ approved in US and Japan, with data showing unprecedented functional cure rates and potential to redefine treatment of chronic hepatitis B | 
| • | _Jemperli_ approved in US as first immunotherapy for adults with dMMR/MSI-H locally advanced rectal cancer | 
| • | Positive registrational data for _Jideytro_ in first-line ROS1-positive non-small cell lung cancer (approved in US in second-line in July) | 
| • | Promising first global data for Ris-Rez in lung cancer; and positive phase I data for Mo-Rez in ovarian cancer | 
| • | _Shingrix_ pre-filled syringe approved in Japan, simplifying administration | 
| • | mRNA seasonal influenza (flu) vaccine phase III trial initiated, following positive phase II data | 
| • | On track to start 22 phase III trials in 2026 with 18 starts to date |

| **Growth outlooks:** | 
| • | 2026 guidance reaffirmed with expected growth in: turnover 3% to 5%; Core OP 7% to 9%; Core EPS 7% to 9% | 
| • | On track for 2031 sales outlook of more than £40 billion | 
| • | Operating margin stable to improving through dolutegravir loss of exclusivity period of 2028-2030 |

| **Shareholder returns:** | 
| • | Q3 2026 dividend of 17p declared; 70p expected for full year 2026 |

> **Luke Miels, Chief Executive Officer, GSK:**“GSK has delivered another strong
> quarter, with our key growth drivers and new launches performing well. We remain
> focused on operational delivery, execution and accelerating R&D. Over recent months
> we have received 3 new specialty medicine approvals in the US: _Hibsago_, which
> has the potential to transform the treatment of chronic hepatitis B; _Jideytro_
> in non-small cell lung cancer; and _Jemperli_ in rectal cancer. More broadly, 
> in the late-stage portfolio, we are on track to start 22 phase III trials this
> year.”

Guidance all at CER. The Total results are presented in summary above and on page
7 and Core results reconciliations are presented on pages 16 and 18. Core results
are a non-IFRS measure that may be considered in addition to, but not as a substitute
for, or superior to, information presented in accordance with IFRS. The following
terms are defined on pages 43-44: Core results, AER% growth, CER% growth and other
non-IFRS measures. GSK provides guidance on a Core results basis only for the reasons
set out on page 14. All expectations, guidance and outlooks regarding future performance
and dividend payments should be read together with ‘Guidance and outlooks, assumptions
and cautionary statements’ on pages 45-46. Abbreviations are defined on page 49.

**2026 Guidance**

GSK reaffirms its full-year 2026 guidance at constant exchange rates (CER).

| **Turnover** is expected to increase between 3% to 5%, at the upper half of the range | 
| **Core operating profit** is expected to increase between 7% to 9%, at the upper half of the range | 
| **Core earnings per share** is expected to increase between 7% to 9%, at the lower half of the range |

This guidance is supported by the following turnover expectations for full-year 
2026 at CER.

| **Specialty Medicines** | – | expected increase at a low double-digit percentage | 
| **Vaccines** | – | expected to be broadly stable to an increase at a low single-digit percentage | 
| **General Medicines** | – | expected decline of a mid-single digit to low single-digit percentage |

Core operating profit is expected to grow at the upper half of the 7 to 9 per cent
range at CER. GSK continues to expect to deliver gross margin accretion due to improved
product mix from Specialty Medicines growth and continued operational efficiencies.
In addition, GSK anticipates further leverage in Operating profit as we accelerate
ongoing productivity initiatives and take a returns-based approach to SG&A investments,
with SG&A expected to be broadly stable year-on-year. R&D is expected to grow significantly
ahead of sales as we accelerate investments in the pipeline as part of the Accelerate
Growth programme while driving operational efficiencies. Royalty income is expected
to be around £900 million.

Core earnings per share is expected to increase at the lower half of the 7 to 9 
per cent range at CER, reflecting higher interest charges of around £700-750 million,
including the impact of the Nuvalent acquisition, and the tax rate which is expected
to rise to around 17.5%, offset by the expected benefit from the share buyback programme.
Expectations for non-controlling interests remain unchanged relative to 2025.

**Agreement with US Government to lower the cost of prescription medicines for American
patients**

As previously announced, on 19 December 2025, GSK entered into an agreement with
the US Administration to lower the cost of prescription medicines for American patients
and exclude both GSK and ViiV Healthcare from Section 232 tariffs for three years.
On 9 April 2026, GSK, ViiV Healthcare, and the US Government entered into a definitive
agreement reflecting Section 232 tariff relief through 20 January 2029 (subject 
to implementation and ongoing compliance). As part of that implementation, GSK and
ViiV Healthcare each signed a GENEROUS Model Manufacturer Participation Agreement
with the Centers for Medicare and Medicaid Services effective 15 June 2026. With
these agreements GSK and ViiV Healthcare have committed certain products to participate
in the voluntary GENEROUS Model. GSK and ViiV have also entered into GENEROUS Model
Supplemental Rebate Agreements with several interested states and will work with
the other states going forward to execute Supplemental Rebate Agreements as requested.
Our full year guidance is inclusive of the expected impact of these agreements.

**Dividend policy**

The Dividend policy and the expected pay-out ratio remain unchanged. Consistent 
with this, GSK has declared a dividend for Q3 2026 of 17p per share. GSK’s future
dividend policy and guidance regarding the expected dividend pay-out in 2026 are
provided on page 30.

GSK completed the £2 billion share buyback programme announced in FY 2024 in Q2 
2026.

**Exchange rates**

If exchange rates were to hold at the closing rates on 30 September 2026 ($1.33/
£1, €1.17/£1 and Yen 209/£1) for the rest of 2026, the estimated impact on 2026 
Sterling turnover growth for GSK would be -1% and if exchange gains or losses were
recognised at the same level as in 2025, the estimated impact on 2026 Sterling Core
Operating Profit growth for GSK would be -3%.

**Results presentation**

A conference call and webcast for investors and analysts of the quarterly results
will be hosted by Luke Miels, CEO, at 12:00 GMT (08:00 EDT) on 28 October 2026. 
Presentation materials will be published on www.gsk.com prior to the webcast and
a transcript of the webcast will be published subsequently.

Notwithstanding the inclusion of weblinks, information available on the company’s
website, or from non GSK sources, is not incorporated by reference into this Results
Announcement.

Share on:
